Literature DB >> 31728366

Pertinent clinical outcomes in pediatric survivors of pediatric acute respiratory distress syndrome (PARDS): a narrative review.

Siew Wah Lee1,2, Sin Wee Loh1, Chengsi Ong3,4, Jan Hau Lee1,5.   

Abstract

The objectives of this review are to describe the limitations of commonly used clinical outcomes [e.g., mortality, ventilation parameters, need for extracorporeal membrane oxygenation (ECMO), pediatric intensive care unit (PICU) and hospital length of stay (LOS)] in pediatric acute respiratory distress syndrome (PARDS) studies; and to explore other pertinent clinical outcomes that pediatric critical care practitioners should consider in future clinical practice and research studies. These include long-term pulmonary function, risk of pulmonary hypertension (PHT), nutrition status and growth, PICU-acquired weakness, neurological outcomes and neurocognitive development, functional status, health-related quality of life (HRQOL)], health-care costs, caregiver and family stress. PubMed was searched using the following keywords or medical subject headings (MESH): "acute lung injury (ALI)", "acute respiratory distress syndrome (ARDS)", "pediatric acute respiratory distress syndrome (PARDS)", "acute hypoxemia respiratory failure", "outcomes", "pediatric intensive care unit (PICU)", "lung function", "pulmonary hypertension", "growth", "nutrition', "steroid", "PICU-acquired weakness", "functional status scale", "neurocognitive", "psychology", "health-care expenditure", and "HRQOL". The concept of contemporary measure outcomes was adapted from adult ARDS long-term outcome studies. Articles were initially searched from existing PARDS articles pool. If the relevant measure outcomes were not found, where appropriate, we considered studies from non-ARDS patients within the PICU in whom these outcomes were studied. Long-term outcomes in survivors of PARDS were not follow-up in majority of pediatric studies regardless of whether the new or old definitions of ARDS in children were used. Relevant studies were scarce, and the number of participants was small. As such, available studies were not able to provide conclusive answers to most of our clinical queries. There remains a paucity of data on contemporary clinical outcomes in PARDS studies. In addition to the current commonly used outcomes, clinical researchers and investigators should consider examining these contemporary outcome measures in PARDS studies in the future. 2019 Annals of Translational Medicine. All rights reserved.

Entities:  

Keywords:  Acute lung injury; acute hypoxemia respiratory failure; acute respiratory distress syndrome (ARDS); outcomes; pediatric acute respiratory distress syndrome (PARDS); pediatric intensive care unit (PICU)

Year:  2019        PMID: 31728366      PMCID: PMC6828794          DOI: 10.21037/atm.2019.09.32

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  71 in total

1.  Early identification of patients at risk of acute lung injury: evaluation of lung injury prediction score in a multicenter cohort study.

Authors:  Ognjen Gajic; Ousama Dabbagh; Pauline K Park; Adebola Adesanya; Steven Y Chang; Peter Hou; Harry Anderson; J Jason Hoth; Mark E Mikkelsen; Nina T Gentile; Michelle N Gong; Daniel Talmor; Ednan Bajwa; Timothy R Watkins; Emir Festic; Murat Yilmaz; Remzi Iscimen; David A Kaufman; Annette M Esper; Ruxana Sadikot; Ivor Douglas; Jonathan Sevransky; Michael Malinchoc
Journal:  Am J Respir Crit Care Med       Date:  2010-08-27       Impact factor: 21.405

2.  Who cares about preventing acute respiratory distress syndrome?

Authors:  Gordon D Rubenfeld
Journal:  Am J Respir Crit Care Med       Date:  2015-02-01       Impact factor: 21.405

3.  The outcomes of children with pediatric acute respiratory distress syndrome: proceedings from the Pediatric Acute Lung Injury Consensus Conference.

Authors:  Michael W Quasney; Yolanda M López-Fernández; Miriam Santschi; R Scott Watson
Journal:  Pediatr Crit Care Med       Date:  2015-06       Impact factor: 3.624

Review 4.  Clinical trials in acute respiratory distress syndrome: challenges and opportunities.

Authors:  Michael A Matthay; Daniel F McAuley; Lorraine B Ware
Journal:  Lancet Respir Med       Date:  2017-05-26       Impact factor: 30.700

5.  Acute cor pulmonale in acute respiratory distress syndrome submitted to protective ventilation: incidence, clinical implications, and prognosis.

Authors:  A Vieillard-Baron; J M Schmitt; R Augarde; J L Fellahi; S Prin; B Page; A Beauchet; F Jardin
Journal:  Crit Care Med       Date:  2001-08       Impact factor: 7.598

6.  Differences Between Pulmonary and Extrapulmonary Pediatric Acute Respiratory Distress Syndrome: A Multicenter Analysis.

Authors:  Chin Seng Gan; Judith Ju-Ming Wong; Rujipat Samransamruajkit; Soo Lin Chuah; Yek Kee Chor; Suyun Qian; Nattachai Anantasit; Xu Feng; Jacqueline Soo May Ong; Phan Huu Phuc; Suwannee Phumeetham; Rehena Sultana; Tsee Foong Loh; Lucy Chai See Lum; Jan Hau Lee
Journal:  Pediatr Crit Care Med       Date:  2018-10       Impact factor: 3.624

7.  Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial.

Authors:  G U Meduri; A S Headley; E Golden; S J Carson; R A Umberger; T Kelso; E A Tolley
Journal:  JAMA       Date:  1998-07-08       Impact factor: 56.272

8.  ICU-Acquired Weakness Is Associated With Differences in Clinical Outcomes in Critically Ill Children.

Authors:  Aida Field-Ridley; Madan Dharmar; David Steinhorn; Craig McDonald; James P Marcin
Journal:  Pediatr Crit Care Med       Date:  2016-01       Impact factor: 3.624

9.  Mortality in Pediatric Acute Respiratory Distress Syndrome: A Systematic Review and Meta-Analysis.

Authors:  Judith Ju-Ming Wong; Mark Jit; Rehena Sultana; Yee Hui Mok; Joo Guan Yeo; Jia Wen Janine Cynthia Koh; Tsee Foong Loh; Jan Hau Lee
Journal:  J Intensive Care Med       Date:  2017-05-01       Impact factor: 3.510

10.  Neonatal corticosteroid therapy affects growth patterns in early infancy.

Authors:  Deodata Tijsseling; Maike Ter Wolbeek; Jan B Derks; Willem B de Vries; Cobi J Heijnen; Frank van Bel; Eduard J H Mulder
Journal:  PLoS One       Date:  2018-02-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.